Oxford Launches Human Trial of Bundibugyo Ebola Vaccine, Bringing a Defense Against a Rare Virus Strain Into the Clinic
The Ebola vaccine landscape has long focused on the Zaire virus; Oxford’s clinical trial of a Bundibugyo candidate vaccine is significant not because it will immediately change outbreak response, but because it begins to fill an immunity gap highlighted by outbreak risk yet supported by limited evidence.